Overview

Open Label Extension Study of Nalbuphine HCl ER in Hemodialysis Patients With Uremic Pruritus

Status:
Completed
Trial end date:
2016-01-01
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to evaluate the overall safety of nalbuphine HCL ER tablets during a treatment period of up to 24 weeks.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Trevi Therapeutics
Treatments:
Nalbuphine